How can there be a worse outcome on one hand and a better outcome on the other?
A contradiction long embedded in oncology — that obesity both elevates cancer risk and improves response to immunotherapy — has found its explanation in the molecular behavior of immune cells. Researchers at Vanderbilt University have traced the paradox to macrophages and a protein called PD-1, which obesity amplifies within tumors, simultaneously suppressing natural immune defenses and creating a more potent target for immunotherapy drugs. The discovery, published in Nature, suggests that the body's metabolic state is not merely a backdrop to cancer but an active participant in how the disease grows and how it may be defeated.
- For years, the obesity-immunotherapy paradox resisted explanation — obesity causes cancer, yet obese patients often beat it more effectively with immunotherapy, a tension that unsettled the logic of treatment.
- Vanderbilt researchers found that obesity floods tumors with macrophages and drives up PD-1 protein production, which silences killer T cells and allows tumors to grow unchecked — the very mechanism behind obesity being the second leading modifiable cancer risk factor.
- The same PD-1 elevation that enables tumor growth becomes a liability when immunotherapy drugs block it, suddenly reactivating macrophages and unleashing killer T cells with amplified force in obese patients.
- A further clue emerged from human tumor data: as patients lost weight, PD-1 expression in tumor macrophages appeared to fall, suggesting the mechanism is dynamic and tied directly to the body's composition.
- The team now believes this biological blueprint could be used to artificially recreate the conditions that make immunotherapy effective, potentially extending its benefits to all patients regardless of weight.
There is a puzzle that has long troubled cancer researchers: obesity raises the risk of developing cancer, yet obese patients often respond better to immunotherapy than leaner ones. Scientists at Vanderbilt University's Medical Center have now found an explanation that may change how doctors approach treatment.
The study, published in Nature, centers on immune cells called macrophages and a protein they produce called PD-1. Examining tumors in mice and kidney cancer patient tissue, the team found that obesity increases both the number of macrophages in tumors and their production of PD-1. This protein suppresses immune surveillance — it mutes the killer T cells responsible for destroying cancer cells, allowing tumors to grow. It is part of why obesity ranks as the second leading modifiable cancer risk factor, behind only smoking.
But the mechanism cuts both ways. When immunotherapy drugs block PD-1, they restore macrophage function and reactivate those same killer T cells — and in obese patients, where PD-1 is already elevated, the effect is amplified. Jeffrey Rathmell, director of Vanderbilt's Center for Immunobiology, framed the central question plainly: 'How can there be a worse outcome on one hand and a better outcome on the other?' The answer is that obesity creates a biological environment that makes immunotherapy unusually potent. Researchers also noted that as patients lost weight, PD-1 expression in tumor macrophages appeared to decline, suggesting the mechanism responds to changes in the body.
Immunotherapy works not by attacking cancer directly but by strengthening the body's own defenses. It is most effective against certain cancers — lung, bladder, melanoma, kidney — and is typically used when conventional treatments have failed. The Vanderbilt team believes that by understanding this mechanism precisely, researchers may one day recreate its conditions artificially, improving immunotherapy outcomes for all patients, not only those living with obesity.
There is a puzzle at the heart of cancer treatment that has long troubled researchers: obesity increases the risk of developing cancer, yet obese patients often respond better to immunotherapy than their leaner counterparts. It is a contradiction that seemed to defy logic. Now scientists at Vanderbilt University's Medical Center have found an explanation that may reshape how doctors think about treating the disease.
The research, published in Nature, centers on immune cells called macrophages and a protein they produce called PD-1. When researchers studied tumors in mice and tissue samples from kidney cancer patients, they discovered that obesity increases the number of macrophages present in tumors and boosts PD-1 production. This finding was unexpected because it revealed a mechanism that works in two opposing directions at once.
Here is how the mechanism unfolds: the elevated PD-1 in obese patients suppresses what researchers call "immune surveillance"—it essentially mutes the activity of killer T cells, the immune cells responsible for destroying cancer cells. This suppression allows tumors to grow unchecked, which helps explain why obesity is the second leading modifiable risk factor for cancer, behind only smoking. But there is a twist. The same PD-1 protein that enables tumor growth becomes a vulnerability when targeted by immunotherapy drugs. When these medications block PD-1, they restore the macrophages' ability to function properly and reactivate the killer T cells. For obese patients, this means their immune systems suddenly become far more effective at fighting cancer.
Jeffrey Rathmell, director of Vanderbilt's Center for Immunobiology, articulated the central mystery: "How can there be a worse outcome on one hand and a better outcome on the other?" The answer lies in understanding that obesity creates a specific biological environment—one that paradoxically makes immunotherapy more potent. When researchers examined human tumors, they found something else revealing: as patients lost weight, PD-1 expression in tumor macrophages appeared to decline. This suggests the mechanism is not fixed but responsive to the body's composition.
Immunotherapy itself represents a fundamental shift in cancer treatment philosophy. Rather than attacking cancer cells directly through chemotherapy or radiation, immunotherapy strengthens the body's own defenses, making them more efficient at detecting and eliminating malignant cells. It is not a universal solution—it works best against lung, bladder, melanoma, stomach, and kidney cancers, and shows promise in triple-negative breast cancer and Hodgkin's lymphoma. The treatment is typically reserved for cases where traditional approaches have failed or when specific genetic markers suggest the tumor will respond to immune activation.
The Vanderbilt team believes their discovery could eventually lead to better immunotherapy treatments for all patients, not just those living with obesity. By understanding the precise biological mechanisms at work, researchers may find ways to artificially recreate the conditions that make immunotherapy effective, potentially improving outcomes across the board. The paradox that seemed to contradict itself now points toward a deeper truth about how the immune system and metabolism interact in the presence of cancer—a truth that could reshape treatment strategies for years to come.
Citas Notables
Understanding how these biological processes work could provide clues about improving immunotherapy in general— Jeffrey Rathmell, director of Vanderbilt's Center for Immunobiology
La Conversación del Hearth Otra perspectiva de la historia
So obesity makes cancer more likely, but then makes the treatment work better? That seems backwards.
It does, until you understand what obesity actually does to the immune cells inside a tumor. It floods them with macrophages that produce a protein called PD-1, which shuts down the immune response. That's why cancer grows. But immunotherapy drugs are designed to block PD-1. So in obese patients, there's more of the target to hit.
But couldn't you just give more of the drug to non-obese patients and get the same effect?
Not necessarily. The amount of PD-1 in the tumor environment matters. It's not just about blocking the protein—it's about the specific immune landscape obesity creates. You can't artificially recreate that in a lean person without understanding the underlying biology first.
What happens if an obese patient loses weight during treatment?
That's the unsettling part. The research showed that weight loss actually decreases PD-1 expression in tumors. So theoretically, losing weight could reduce the very thing making the immunotherapy effective. It raises hard questions about timing and strategy.
So doctors might have to choose between two good outcomes?
Exactly. Better immune response now, or better long-term health outcomes later. That's why understanding the mechanism matters—it might let us preserve the benefits of immunotherapy without relying on obesity itself.